Key Results
Financial Highlights
2,341.6
Net Revenue (Million Euros)
+12.4% versus FY 2023
568.9
Adj. Net Income (Million Euros)
+8.4% versus FY 2023
865.8
EBITDA (Million Euros)
+12.5% versus FY 2023
“2024 exemplified Recordati’s ongoing dedication to achieving profitable and sustainable growth. We expect to maintain this positive momentum through to 2025, continuing to focus on enhancing performance whilst advancing and strengthening our business operations”
Luigi La Corte
Chief Financial Officer
Revenue
Million Euros
EBITDA*
Million Euros
EBITDA* AS % OF REVENUE
:
RESEARCH & DEVELOPMENT
Million Euros
NET INCOME
Million Euros
ADJUSTED NET INCOME**
Million Euros
dividend per share
Euro
NET INCOME per share
Euro
ADJUSTED NET INCOME per share
Euro
* Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and no-cash charges arising from the allocation of the purchase pice of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3.
Balance Sheet
at 31 December 2024
No Data Found
No Data Found
1,876.8
Shareholder Equity (Million Euros)
2,154.3
Net Financial Position (Million Euros)
Pharmaceutical Revenue by Therapeutic Area
The Group’s pharmaceutical business includes two segments: Specialty & Primary Care and Rare Diseases.
SPECIALTY & PRIMARY CARE 64.4%
RARE DISEASES 35.6%
Key Results
Revenue by Therapeutic Area
Specialty & Primary Care
The Specialty & Primary Care (SPC) business delivered an excellent performance in 2024 with revenue totalling €1,449.2 million, growing 10.3% or 5.7% on a like-for-like basis at CER (+2.5% excluding Türkiye).
This reflects strong performance from the Urology and uro-oncology franchise with 42.6% growth versus the previous year, driven by the double-digit growth of Eligard® and the € 111.6 million contribution of Avodart® and Combodart®/Duodart®. The Cardiovascular franchise delivered mid-single digit growth, while the Cough and Cold business reflected strong performance in the fourth quarter which brought FY 2024 in-line with FY 2023 levels.
“Our Specialty & Primary Care business continued to deliver a strong performance in 2024, supported by particularly strong growth of Eligard®, as we successfully launched its new device. With over 100 million people benefitting from our treatments, we are truly redefining excellence in Specialty & Primary Care.”
Alberto Martinez
Executive Vice President, Specialty & Primary Care
The table below shows Specialty & Primary Care revenue in 2024, broken down by therapeutic area, compared to the previous year. The segment shows revenue increase of 10.2%.
Loading..........
The Data is Not Available
Rare Diseases
In 2024, revenue for Rare Diseases reached € 833.9 million, marking a 16.7% increase compared to the previous year. This growth reflects the addition of Enjaymo® (€ 10.9 million) for the single month of December 2024, following the execution of the Asset Purchase Agreement with Sanofi at the end of November.The like-for-like growth at constant exchange rates of 15.7% is driven by a robust volume growth of both Endocrinology and Oncology franchises, thanks also to the greater awareness and improvement in diagnosis and treatment of these diseases.
“We’re delighted with the continued double-digit growth across Rare Diseases in 2024, driven by strong performances in our Endocrinology and Hema-Oncology Franchises. We’ve also expanded our Hema-Oncology franchise with the acquisition of Enjaymo®. More than 16,000 patients now benefit from our treatments, with our ultimate goal to leave no patient behind.”
Scott Pescatore
Executive Vice President, Rare Diseases
Loading..........
The Data is Not Available
* Isturisa® € 203.6 million and Signifor® € 118.0 million in 2024, compared to € 139.5 million and € 102.9 million, respectively, in 2023.
Key Results
Revenue by Geography
Pharmaceutical sales by geographic area for the different Recordati Group subsidiaries are listed in the table and graph below:
Loading..........
The Data is Not Available
Net revenue includes the sales of products and various revenue excluding Pharmaceutical Chemicals.
Excluding sales of pharmaceutical chemicals, which were at € 58.5 million, up by 8.2%, representing 2.5% of total revenue.